undamentalytics Newsletter

Williams Timothy: insider trades

Officer at Vanda Pharmaceuticals Inc. No open-market purchases and 13 sales not made under a pre-set plan, reported from August 15, 2019 to March 4, 2026.

What happened after Williams Timothy’s sales?

After their sales, the shares moved −34.6% against the index over 12 months on average (a negative figure means selling was the right call); 82% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

Trade by trade

Williams Timothy: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 0 — — — — — — Not enough years
Purchases, 6 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the report 0 — — — — — — Not enough years
Purchases, 12 months after the trade 0 — — — — — — Not enough years
Sales, 3 months after the report 12 −7.0% −6.4% 75% 6 −1.64 0.16 No reliable evidence
Sales, 12 months after the report 11 −34.6% −42.6% 82% 5 −2.24 0.088 No reliable evidence
Sales, 12 months after the trade 11 −35.1% −40.7% 82% 5 −2.50 0.067 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Vanda Pharmaceuticals Inc. VNDA SVP & General Counsel013August 15, 2019March 4, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
March 4, 2026March 2, 2026 VNDA Sale $350,929 −32.4%not yetnot yet
March 6, 2024March 4, 2024 VNDA Sale $73,302 not yetnot yetnot yet
June 15, 2023June 13, 2023 VNDA Sale $95,776 −31.0%−26.1%−26.6%
March 6, 2023March 2, 2023 VNDA Sale $104,528 −8.4%−70.4%−63.1%
December 16, 2022December 15, 2022 VNDA Sale $56,080 −12.6%−72.4%−68.2%
August 17, 2022August 15, 2022 VNDA Sale $85,518 +7.5%−47.2%−49.1%
March 2, 2022March 2, 2022 VNDA Sale $133,745 −5.9%−36.8%−36.6%
August 17, 2021August 16, 2021 VNDA Sale $59,997 +4.4%−32.5%−33.3%
March 8, 2021March 5, 2021 VNDA Sale $99,966 −6.9%−48.1%−54.8%
March 3, 2021March 1, 2021 VNDA Sale $362,798 −8.6%−54.3%−53.0%
August 17, 2020August 14, 2020 VNDA Sale $43,508 +15.8%+15.0%+4.7%
March 4, 2020March 2, 2020 VNDA Sale $45,425 0.0%+35.4%+34.0%
August 15, 2019August 14, 2019 VNDA Sale $37,827 −5.7%−42.6%−40.7%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Williams Timothy traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.